“Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study”, J of Skin, vol. 9, no. 6, p. s604, Nov. 2025, doi: 10.25251/2ddr5090.